Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endocine
- Development stage
- Unknown
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intranasal
01
Overview
Endocine is a lipid-based mucosal adjuvant designed to enhance immune responses. It is administered intranasally and has been studied in conjunction with therapeutic HIV vaccines (Vacc-4x) and influenza antigens to induce both systemic and mucosal immunity. Its mechanism of action involves mediating RNA release, which subsequently activates dendritic cells, thereby improving vaccine efficacy, particularly in populations like the elderly.
- Brand names
- Endocine™
Beyond the preview
Go deeper on Endocine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endocine.